Recombinant programmed cell death protein 1 functions as an immune check point blockade and enhances anti-cancer...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapy, including immune checkpoint blockade, shows promise but has limitations in treating metastatic and recurrent cancers.
• Recombinant murine programmed death-1 (rmPD-1) proteins are explored as a potential therapeutic agent.
• Targeting immune checkpoints is crucial for enhancing anti-tumor immunity.

Purpose of the Study:

• To investigate the efficacy of rmPD-1 as an immune checkpoint blockade.
• To develop and evaluate rmPD-1 decorated thermal responsive hybrid nanoparticles (piHNPs) for cancer therapy.
• To assess the potential of piHNPs in preventing cancer metastasis and recurrence.

Main Methods:

• Extraction and characterization of rmPD-1 proteins.
• Assessment of rmPD-1 binding to cancer cells expressing PD-L1 and PD-L2.
• Evaluation of rmPD-1's effect on dendritic cell activation and T cell-mediated immunity in CT-26 tumor models.
• Development of rmPD-1 decorated piHNPs for laser-triggered therapy.
• Assessment of piHNP anti-tumor effects, including induction of apoptosis and necrosis.
• Evaluation of piHNP efficacy in preventing primary tumor growth, lung metastasis, and recurrence in CT-26 and 4T1 models.
• Investigation of the role of cancer antigen-specific memory T cell immunity.

Main Results:

• rmPD-1 effectively bound to CT-26 and 4T1 cells expressing PD-L1 and PD-L2.
• rmPD-1 promoted T cell-mediated anti-cancer immunity against CT-26 tumors without altering dendritic cell activation.
• rmPD-1 decorated piHNPs induced apoptotic and necrotic cell death in CT-26 cells upon laser irradiation, enhancing anti-tumor effects.
• Mice treated with piHNPs were protected from primary CT-26 tumor challenge and subsequent lung metastatic growth.
• Cancer antigen-specific memory T cell immunity was crucial for preventing metastatic tumor growth.
• piHNP treatment also prevented lung metastatic growth of 4T1 breast cancer in cured mice.

Conclusions:

• rmPD-1 functions as an effective immune checkpoint blockade for tumor treatment.
• rmPD-1 decorated piHNPs represent a novel therapeutic strategy for combating primary tumors.
• piHNPs demonstrate significant potential in preventing cancer metastasis and recurrence through the induction of immune memory.